Show results for
Refine by
Disease Development Equipment Supplied In Sweden
8 equipment items found
Manufactured by:BioArctic AB based inStockholm, SWEDEN
The antibody PD1601 is targeting alpha-synuclein for treatment of Parkinson’s disease. The aim is to develop a disease modifying treatment that stops or slows down disease progression. The project is conducted in collaboration with ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
The antibody PD1602 is targeting alpha-synuclein for treatment of Parkinson’s disease. The aim is to develop a disease modifying treatment that stops or slows down disease progression. The project is conducted in collaboration with ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
AD1503 is an innovative project to develop a disease modifying treatment for prodromal and mild Alzheimer’s disease. ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
AD1502 is an innovative project to develop a disease modifying treatment for prodromal and mild Alzheimer’s disease. ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
The drug candidate ABBV-0805 is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. The goal is to develop a disease modifying treatment that stops or slows down disease ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
AD1801 is an innovative project to develop disease modifying treatment of Alzheimer’s disease, targeting Apolipoprotein E (ApoE), a different molecule than those targeted in the projects BAN2401 and BAN2401 ...
Manufactured by:Olink Proteomics based inUppsala, SWEDEN
The most comprehensive, high-performance protein biomarker panels available for neurological studies. The flexibility and scalability of our Olink® Explore platform can be utilized either to screen our entire library of 3072 assays, or in studies that focus on one or several of the eight Explore 384-plex panels that make up the Explore 3072 protein ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
Research to develop new antibodies for treating neurodegenerative disorders is under way at BioArctic. the ND3014 project aims to develop selective antibody treatments targeting TDP-43, a protein that is believed to play a crucial role in the development of the rare neurodegenerative disease ALS (amyotrophic lateral ...